View ValuationNeuphoria Therapeutics 将来の成長Future 基準チェック /06Neuphoria Therapeuticsの収益は年間4.3%で減少すると予測されていますが、年間収益は年間118.1%で増加すると予想されています。EPS は年間31.3%で増加すると予想されています。主要情報-4.3%収益成長率31.28%EPS成長率Biotechs 収益成長25.4%収益成長率118.1%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日15 May 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updates分析記事 • Feb 19Neuphoria Therapeutics (NASDAQ:NEUP) Is In A Strong Position To Grow Its BusinessJust because a business does not make any money, does not mean that the stock will go down. For example, although...お知らせ • Jan 08+ 1 more updateNeuphoria Therapeutics Inc. Announces Executive Changes Effective January 1, 2026Neuphoria Therapeutics Inc. terminated Spyridon "Spyros" Papapetropoulos' employment as President and Chief Executive Officer effective December 31, 2025, and Mr. Papapetropoulos will remain as a member of the Company's Board of Directors. Effective January 1, 2026, Mr. Papapetropoulos entered into a Consulting Agreement with the Company under which he will serve as interim CEO for up to twelve months to support the execution of the Company's contemplated strategic transaction and ensure a seamless transition. All post-termination obligations of Independent Contractor under the Prior Employment Agreement, including the Proprietary Information and Inventions Agreement executed in conjunction with the Prior Employment Agreement, and including without limitation provisions relating to confidentiality, non-disclosure, protection of trade secrets, intellectual property, non-disparagement, cooperation, and return of Company property, shall continue in full force and effect and are hereby incorporated by reference.お知らせ • Dec 03+ 1 more updateLynx1 Master Sends a Letter to the Shareholders of Neuphoria TherapeuticsOn December 2, 2025, Lynx1 Master Fund LP sent an open letter to the shareholders of Neuphoria Therapeutics Inc., detailing why it is calling for change at the Company. In the letter, Lynx1 noted that the Company's board of directors has demonstrated a pattern of mismanagement that has led to clinical failures and an opaque review of strategic alternatives. Lynx1 resubmitted its offer to acquire all of the outstanding shares of the Company for $4.75 per share in cash, preserving the economics of its initial offer which was withdrawn due to the Board's intervening actions. Lynx1 also noted it has nominated two highly qualified, independent director candidates, Dr. Stephen Doberstein and Kimberly Smith, for election to the Board at the Company's 2025 annual meeting of shareholders. Lynx1 urged shareholders to vote FOR its independent nominees on the BLUE universal proxy card to restore accountability and maximize value amid the Company's ongoing strategic review.分析記事 • Nov 05Does This Valuation Of Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Imply Investors Are Overpaying?Key Insights Neuphoria Therapeutics' estimated fair value is US$3.35 based on 2 Stage Free Cash Flow to Equity...お知らせ • Oct 31Neuphoria Therapeutics Inc., Annual General Meeting, Dec 09, 2025Neuphoria Therapeutics Inc., Annual General Meeting, Dec 09, 2025.お知らせ • Oct 21Neuphoria Therapeutics Provides Update on Affirm-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety DisorderNeuphoria Therapeutics Inc. announced that the AFFIRM-1 Phase 3 trial of BNC210 for the acute treatment of social anxiety disorder (SAD) did not meet its primary endpoint of change from baseline to the average of the performance phase of the public speaking challenge in Subjective Units of Distress Scale (SUDS) scores. In addition, analyses of secondary endpoints did not demonstrate statistically significant differences. The Company expects its current cash position to be sufficient to fund operations through the second fiscal quarter of 2027. The AFFIRM-1 phase 3 clinical trial was a multi-center, double-blind, two-arm, parallel group, placebo-controlled trial evaluating the safety and efficacy of a single, acute dose of 225 mg of BNC210 versus placebo. Participants in the trial were randomized 1:1 to receive a single dose of 225 mg BNC210 or matched placebo. The primary endpoint of the trial was the change from baseline to the average the performance phase of the public speak challenge in Subjective Units of distress Scale (SUDS) score. Secondary endpoints included change in SUDS score from baseline to the average of The anticipation phase, changes in the Clinical Global Impression - Severity (CGI-S) scale, self-assessment with the State Trait Anxiety Inventory (STAI-State) and the Patient Global Impression - Improvement (PGI-I) scale. A follow-up visit occurred one week after the public speaking challenge.お知らせ • Sep 17Nasdaq Grants Neuphoria Therapeutics Inc. an Extension of 180 Calendar Days to Regain Compliance with the Listing RuleAs previously disclosed on July 18, 2025, Neuphoria Therapeutics Inc. (the Company") received a deficiency notification letter (the Notice") from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq"). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5620(a) (the Listing Rule") as a result of the Company's failure to hold an annual general meeting of stockholders within twelve months of the end of the Company's fiscal year ended June 30, 2024. The Listing Rule requires that a Nasdaq-listed company hold an annual meeting of shareholders no later than one year after the end of the company's fiscal year end. Pursuant to and in response to that Notice, the Company timely submitted its plan to Nasdaq to regain compliance with the Listing Rule (the Plan"). In response to the Company's Plan, on September 10, 2025, Nasdaq provided the Company further notice that is has accepted our Plan and granted the Company an extension of 180 calendar days (the Compliance Period") from the end of the Company's fiscal year, or until December 29, 2025, to regain compliance with the Listing Rule. To this end, the Company intends to file its annual report on Form 10-K on or before September 29, 2025, and thereafter, the Company intends to timely file a proxy statement and notice of shareholder meeting related to the Company's 2025 annual general shareholder meeting, and further intends to hold such annual shareholder meeting within the Compliance Period.お知らせ • Sep 04Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)Neuphoria Therapeutics Inc. announced the achievement of target enrollment of 332 participants in the AFFIRM-1 Phase 3 trial evaluating lead candidate BNC-210 as a first-in-class, acute, "as needed", fast-acting treatment for social anxiety disorder (SAD). BNC-210 is an oral, proprietary, selective negative allosteric modulator of the a7 nicotinic acetylcholine receptor under development for the treatment of SAD and post-traumatic stress disorder (PTSD). BNC-210 has been given FDA Fast Track designation for acute treatment of SAD and other anxiety related disorders, and for treatment of PTSD and other trauma and stressor related disorders. BNC-210 has demonstrated rapid-onset, broad and meaningful anti-an anxiety effects in completed clinical trials in SAD, generalized anxiety disorder (GAD) and panic attacks without evidence of sedation, impairments in cognition or addiction potential. The AFFIRM-1 phase 3 clinical trial is a multi-center, double-blind, two-arm, parallel group, placebo-controlled trial evaluating the safety and efficacy of a single, acute dose of 225 mg of BNC-210 versus placebo. Participants in the trial are randomized 1:1 to receive a single dose of 225 mg BNC-210 or matched placebo. The primary endpoint of the trial is the change from baseline to the average of the performance phase of the public speaking challenge in Subjective Units of Distress Scale (SUDS) scores. Secondary endpoints include change in SUDS score from baseline to the average of The Clinical Global Impression - Severity (CGI-S) scale, and self-assessment with the State Trait Anxiety Inventory (STAI-State) and the Patient Global Impression - Improvement (PGI-I) scale. A follow-up visit occurs one week after the public speaking challenge. SAD can interfere with a person's ability to work, make it difficult to maintain relationships, family relationships, and romantic partnerships, cause a person to avoid lifestyle activities like dining out and traveling, and make normal parts of everyday life such as grocery shopping, calling a handyman, or picking up coffee challenging.お知らせ • Jul 30Neuphoria Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $6.337229 million.Neuphoria Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $6.337229 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offeringお知らせ • Jul 21Neuphoria Therapeutics Receives a Deficiency Notification Letter from the Listing Qualifications Staff of the Nasdaq Stock MarketOn July 18, 2025, Neuphoria Therapeutics Inc. received a deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC. The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5620(a) (the “Listing Rule”) as a result of the Company’s failure to hold an annual meeting of stockholders within twelve months of the end of the Company’s fiscal year ended June 30, 2024. The Listing Rule requires that a Nasdaq-listed company hold an annual meeting of shareholders no later than one year after the end of the company’s fiscal year end. The Company notes that it has held a shareholder meeting every year for the past number of years on or about November or December of each such year, including the extensive shareholder meeting we held in relation to our redomicilation and scheme of arrangement to become a Delaware corporation in December 2024. To this end, the Company had already planned to hold its 2025 annual general shareholder meeting on or about November 2025, in-line with past annual shareholder meeting dates, in satisfaction of the compliance item provided in the Notice and which will be consistent with the Plan (defined below) that the Company intends to submit on a timely basis. The Company also looks forward to timely filing its annual report on or before September 30, 2025, as well as its upcoming annual shareholder meeting communication(s) shortly thereafter. The Company has until September 1, 2025 to submit a plan to regain compliance with the Listing Rule (the “Plan”). Pursuant to the Notice, if Nasdaq accepts the Plan, Nasdaq has the discretion to grant the Company an exception of up to 180 calendar days (the “Compliance Period”) from the end of the Company’s fiscal year, or until December 29, 2025, to regain compliance with the Listing Rule. The Notice has no immediate effect on the listing of the Company’s common stock on Nasdaq.お知らせ • May 16Neuphoria Therapeutics Inc. announced delayed 10-Q filingOn 05/15/2025, Neuphoria Therapeutics Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 20Bionomics Limited has filed a Follow-on Equity Offering in the amount of $2 million.Bionomics Limited has filed a Follow-on Equity Offering in the amount of $2 million. Security Name: American Depositary Shares Security Type: Depositary Receipt (Common Stock) Transaction Features: At the Market Offering業績と収益の成長予測NasdaqGM:NEUP - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/2028N/A-20N/AN/A16/30/2027N/A-17N/AN/A16/30/2026N/A-19N/AN/A13/31/20260-17-17-17N/A12/31/202515-6-2-2N/A9/30/202516-911N/A6/30/202516000N/A3/31/202516611N/A12/31/20241-8-14-14N/A9/30/2024N/A-11-15-15N/A6/30/2024N/A-15-15-15N/A3/31/20240-18-16-16N/A12/31/20230-20-17-17N/A9/30/20230-22-16-16N/A6/30/2023N/A-21-15-15N/A3/31/20232-19-13-13N/A12/31/20224-17-12-12N/A9/30/20224-15-13-13N/A6/30/20224-15-15-15N/A3/31/20222-16-15-15N/A12/31/20210-16-14-14N/A9/30/20211-11-10-10N/A6/30/20211-7-6-6N/A3/31/20211-3N/AN/AN/A12/31/202011-4-4N/A9/30/20202-2-3-3N/A6/30/20202-4-3-3N/A12/31/20194-3N/A-6N/A9/30/20195-5N/A-8N/A6/30/20195-7N/A-11N/A3/31/20196-14N/A-11N/A12/31/20185-20N/A-10N/A9/30/20187-19N/A-13N/A6/30/20189-19N/A-15N/A3/31/201815-12N/A-12N/A12/31/201721-5N/A-8N/A9/30/201721-5N/A-5N/A6/30/201721-5N/A-1N/A3/31/201717-9N/A-5N/A12/31/201612-12N/A-9N/A9/30/201614-13N/A-11N/A6/30/201614-12N/A-11N/A3/31/201614-14N/A-13N/A12/31/201513-15N/A-13N/A9/30/201512-13N/A-5N/A6/30/201512-13N/A4N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: NEUP今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: NEUP今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: NEUP今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: NEUP来年は収益がないと予測されています。高い収益成長: NEUP来年は収益がないと予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: NEUPの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 00:41終値2026/05/22 00:00収益2026/03/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Neuphoria Therapeutics Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Tanushree JainBell PotterEsther Lannie HongBerenbergKatherine GenisEdison Investment Research2 その他のアナリストを表示
分析記事 • Feb 19Neuphoria Therapeutics (NASDAQ:NEUP) Is In A Strong Position To Grow Its BusinessJust because a business does not make any money, does not mean that the stock will go down. For example, although...
お知らせ • Jan 08+ 1 more updateNeuphoria Therapeutics Inc. Announces Executive Changes Effective January 1, 2026Neuphoria Therapeutics Inc. terminated Spyridon "Spyros" Papapetropoulos' employment as President and Chief Executive Officer effective December 31, 2025, and Mr. Papapetropoulos will remain as a member of the Company's Board of Directors. Effective January 1, 2026, Mr. Papapetropoulos entered into a Consulting Agreement with the Company under which he will serve as interim CEO for up to twelve months to support the execution of the Company's contemplated strategic transaction and ensure a seamless transition. All post-termination obligations of Independent Contractor under the Prior Employment Agreement, including the Proprietary Information and Inventions Agreement executed in conjunction with the Prior Employment Agreement, and including without limitation provisions relating to confidentiality, non-disclosure, protection of trade secrets, intellectual property, non-disparagement, cooperation, and return of Company property, shall continue in full force and effect and are hereby incorporated by reference.
お知らせ • Dec 03+ 1 more updateLynx1 Master Sends a Letter to the Shareholders of Neuphoria TherapeuticsOn December 2, 2025, Lynx1 Master Fund LP sent an open letter to the shareholders of Neuphoria Therapeutics Inc., detailing why it is calling for change at the Company. In the letter, Lynx1 noted that the Company's board of directors has demonstrated a pattern of mismanagement that has led to clinical failures and an opaque review of strategic alternatives. Lynx1 resubmitted its offer to acquire all of the outstanding shares of the Company for $4.75 per share in cash, preserving the economics of its initial offer which was withdrawn due to the Board's intervening actions. Lynx1 also noted it has nominated two highly qualified, independent director candidates, Dr. Stephen Doberstein and Kimberly Smith, for election to the Board at the Company's 2025 annual meeting of shareholders. Lynx1 urged shareholders to vote FOR its independent nominees on the BLUE universal proxy card to restore accountability and maximize value amid the Company's ongoing strategic review.
分析記事 • Nov 05Does This Valuation Of Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Imply Investors Are Overpaying?Key Insights Neuphoria Therapeutics' estimated fair value is US$3.35 based on 2 Stage Free Cash Flow to Equity...
お知らせ • Oct 31Neuphoria Therapeutics Inc., Annual General Meeting, Dec 09, 2025Neuphoria Therapeutics Inc., Annual General Meeting, Dec 09, 2025.
お知らせ • Oct 21Neuphoria Therapeutics Provides Update on Affirm-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety DisorderNeuphoria Therapeutics Inc. announced that the AFFIRM-1 Phase 3 trial of BNC210 for the acute treatment of social anxiety disorder (SAD) did not meet its primary endpoint of change from baseline to the average of the performance phase of the public speaking challenge in Subjective Units of Distress Scale (SUDS) scores. In addition, analyses of secondary endpoints did not demonstrate statistically significant differences. The Company expects its current cash position to be sufficient to fund operations through the second fiscal quarter of 2027. The AFFIRM-1 phase 3 clinical trial was a multi-center, double-blind, two-arm, parallel group, placebo-controlled trial evaluating the safety and efficacy of a single, acute dose of 225 mg of BNC210 versus placebo. Participants in the trial were randomized 1:1 to receive a single dose of 225 mg BNC210 or matched placebo. The primary endpoint of the trial was the change from baseline to the average the performance phase of the public speak challenge in Subjective Units of distress Scale (SUDS) score. Secondary endpoints included change in SUDS score from baseline to the average of The anticipation phase, changes in the Clinical Global Impression - Severity (CGI-S) scale, self-assessment with the State Trait Anxiety Inventory (STAI-State) and the Patient Global Impression - Improvement (PGI-I) scale. A follow-up visit occurred one week after the public speaking challenge.
お知らせ • Sep 17Nasdaq Grants Neuphoria Therapeutics Inc. an Extension of 180 Calendar Days to Regain Compliance with the Listing RuleAs previously disclosed on July 18, 2025, Neuphoria Therapeutics Inc. (the Company") received a deficiency notification letter (the Notice") from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq"). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5620(a) (the Listing Rule") as a result of the Company's failure to hold an annual general meeting of stockholders within twelve months of the end of the Company's fiscal year ended June 30, 2024. The Listing Rule requires that a Nasdaq-listed company hold an annual meeting of shareholders no later than one year after the end of the company's fiscal year end. Pursuant to and in response to that Notice, the Company timely submitted its plan to Nasdaq to regain compliance with the Listing Rule (the Plan"). In response to the Company's Plan, on September 10, 2025, Nasdaq provided the Company further notice that is has accepted our Plan and granted the Company an extension of 180 calendar days (the Compliance Period") from the end of the Company's fiscal year, or until December 29, 2025, to regain compliance with the Listing Rule. To this end, the Company intends to file its annual report on Form 10-K on or before September 29, 2025, and thereafter, the Company intends to timely file a proxy statement and notice of shareholder meeting related to the Company's 2025 annual general shareholder meeting, and further intends to hold such annual shareholder meeting within the Compliance Period.
お知らせ • Sep 04Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)Neuphoria Therapeutics Inc. announced the achievement of target enrollment of 332 participants in the AFFIRM-1 Phase 3 trial evaluating lead candidate BNC-210 as a first-in-class, acute, "as needed", fast-acting treatment for social anxiety disorder (SAD). BNC-210 is an oral, proprietary, selective negative allosteric modulator of the a7 nicotinic acetylcholine receptor under development for the treatment of SAD and post-traumatic stress disorder (PTSD). BNC-210 has been given FDA Fast Track designation for acute treatment of SAD and other anxiety related disorders, and for treatment of PTSD and other trauma and stressor related disorders. BNC-210 has demonstrated rapid-onset, broad and meaningful anti-an anxiety effects in completed clinical trials in SAD, generalized anxiety disorder (GAD) and panic attacks without evidence of sedation, impairments in cognition or addiction potential. The AFFIRM-1 phase 3 clinical trial is a multi-center, double-blind, two-arm, parallel group, placebo-controlled trial evaluating the safety and efficacy of a single, acute dose of 225 mg of BNC-210 versus placebo. Participants in the trial are randomized 1:1 to receive a single dose of 225 mg BNC-210 or matched placebo. The primary endpoint of the trial is the change from baseline to the average of the performance phase of the public speaking challenge in Subjective Units of Distress Scale (SUDS) scores. Secondary endpoints include change in SUDS score from baseline to the average of The Clinical Global Impression - Severity (CGI-S) scale, and self-assessment with the State Trait Anxiety Inventory (STAI-State) and the Patient Global Impression - Improvement (PGI-I) scale. A follow-up visit occurs one week after the public speaking challenge. SAD can interfere with a person's ability to work, make it difficult to maintain relationships, family relationships, and romantic partnerships, cause a person to avoid lifestyle activities like dining out and traveling, and make normal parts of everyday life such as grocery shopping, calling a handyman, or picking up coffee challenging.
お知らせ • Jul 30Neuphoria Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $6.337229 million.Neuphoria Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $6.337229 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
お知らせ • Jul 21Neuphoria Therapeutics Receives a Deficiency Notification Letter from the Listing Qualifications Staff of the Nasdaq Stock MarketOn July 18, 2025, Neuphoria Therapeutics Inc. received a deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC. The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5620(a) (the “Listing Rule”) as a result of the Company’s failure to hold an annual meeting of stockholders within twelve months of the end of the Company’s fiscal year ended June 30, 2024. The Listing Rule requires that a Nasdaq-listed company hold an annual meeting of shareholders no later than one year after the end of the company’s fiscal year end. The Company notes that it has held a shareholder meeting every year for the past number of years on or about November or December of each such year, including the extensive shareholder meeting we held in relation to our redomicilation and scheme of arrangement to become a Delaware corporation in December 2024. To this end, the Company had already planned to hold its 2025 annual general shareholder meeting on or about November 2025, in-line with past annual shareholder meeting dates, in satisfaction of the compliance item provided in the Notice and which will be consistent with the Plan (defined below) that the Company intends to submit on a timely basis. The Company also looks forward to timely filing its annual report on or before September 30, 2025, as well as its upcoming annual shareholder meeting communication(s) shortly thereafter. The Company has until September 1, 2025 to submit a plan to regain compliance with the Listing Rule (the “Plan”). Pursuant to the Notice, if Nasdaq accepts the Plan, Nasdaq has the discretion to grant the Company an exception of up to 180 calendar days (the “Compliance Period”) from the end of the Company’s fiscal year, or until December 29, 2025, to regain compliance with the Listing Rule. The Notice has no immediate effect on the listing of the Company’s common stock on Nasdaq.
お知らせ • May 16Neuphoria Therapeutics Inc. announced delayed 10-Q filingOn 05/15/2025, Neuphoria Therapeutics Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 20Bionomics Limited has filed a Follow-on Equity Offering in the amount of $2 million.Bionomics Limited has filed a Follow-on Equity Offering in the amount of $2 million. Security Name: American Depositary Shares Security Type: Depositary Receipt (Common Stock) Transaction Features: At the Market Offering